Summary
Transformation of hematopoietic cells by the p210bcr lab' tyrosine kinase appears to require the expression of a functional MYC protein, suggesting that simultaneous targeting of BCR-ABL and c-myc might be a rational strategy for attempting treatment of Phil-adelphial leukemia . To test this hypothesis, severe combined immunodeficiency mice injected with Philadelphia' leukemic cells were treated systemically with equal doses ofbcr-abl or c-myc antisense oligodeoxynucleotides (ODNs) or with both ODNs in combination . Compared with the mice treated with individual agents, the disease process was much slower in the group treated with both ODNs, as revealed by flow cytometry, clonogenic assay, and reverse transcriptase-polymerase chain reaction analysis to detect leukemic cells in mouse tissue cell suspensions, and by enumeration of liver metastases. The retardation of the disease process was positively correlated with a markedly increased survival of leukemic mice treated with both ODNs . These data demonstrate the therapeutic potential of targeting multiple cooperating oncogenes .
rowing evidence suggests that cancer arises through a multistep process that involves activation of protooncogenes and loss of function of tumor suppressor genes (1, 2) . Oncogene cooperation was originally demonstrated in vitro (3) (4) (5) and subsequently validated in vivo using transgenic mouse models (6) . Chronic myelogenous leukemia (CML)' illustrates well the concept of a multistep process in human malignancies, because the clinical course consists of two well-defined stages, i.e., a relatively indolent and long-lasting chronic phase and a terminal, more aggressive blast crisis (7) . At the genetic level, the predominant abnormality of the chronic phase is the Philadelphia chromosome (Ph') translocation, resulting in the formation of the BCR-ABL oncogene . BCR-ABL expression determines the growth advantage ofPhiladelphia' cells in part by protecting them from apoptosis (8) (9) (10) . In blast crisis, several other abnormalities might be present, including inactivation ofthe p53 tumor suppressor gene, chromosomal trisomy, and additional translocations (11) (12) (13) . Several lines of evidence also suggest that MYC cooperates with and is re-'Abbreviations used in this paper: AS, antisense ; BMC, bone marrow cell; CML, chronic myelogenous leukemia ; ODN, oligodeoxynucleotide; PBL, peripheral blood leukocyte ; Ph', Philadelphia chromosome ; Qt/ RT-PCR, quantitative PT-PCR ; RT, reverse transcriptase; S, sense ; [S]ODN, phosphorothioate ODN ; SPL, spleen; TBS, Tris-buffered saline .
quired for BCR-ABL or v-ABL transformation of hematopoietic and nonhematopoietic cells (14) (15) (16) (17) (18) . Thus, to test whether simultaneous targeting ofBCR-ABL (the initiating agent of the disease process) and c-myc (a transcriptional end point of BCR-ABL-mediated events) in CML cells represents a novel and effective modality of leukemia treatment, we compared the effects of phosphorothioate bcr-abl and c-myc antisense (AS) oligodeoxynucleotides (ODNs) alone and in combination in vitro and on leukemia development in immunodeficient (SCID) mice.
Materials and Methods
Mice and Leukemia Cells . Outbred ICR-SCID male mice (7-9 wk old from Taconic Farms, Inc ., Germantown, NY) and BV173 leukemic cells were used as previously described (19) . According to testing performed by the vendor, the frequency of "leaky" SCID mice in the population is <1%.
ODNs . ODNs were prepared on an automated synthesizer (model 390Z; Applied Biosystems, Foster City, CA) . The bcr-abl (26-mer, b2/a2) and c-myc (26-mer from the initiation codon) sense (S) and AS phosphorothioate ODNs ([S]ODNs) were described previously (19, 20) . Sequences of the 3' primer of ABL exon 2 3' primer of [3-actin, 5' primers of BCR exon 2 and 5' primer of [3-actin, and the ABL and [3-actin probes recognizing amplified transcripts have been published (21, 22 (19) .
Quantitative RT-PCR (Qt/RT-PCR) . Total RNA from 5 X 106 bone marrow cells of b2/a2 AS-and b2/a2 plus c-myc AStreated mice was extracted and adjusted to the same concentration, and equal amounts of [3-actin were detected in 1 p.l of each sample by RT-PCR to confirm the same quality of isolated RNA. The material was divided into five equal samples, and an increasing amount (from 0 to 100 ng) of total RNA from K562 cells (b3/a2 junction) was added to each sample as a source of competitive RNA. RT-PCR performed using a 3' primer from ABL exon 2 and a 5' primer from BCR exon 2 generated two cDNA fragments, 257-bp b2/a2 and 332-bp b3/a2, during 25 cycles of PCR amplification. Fragments were detected by Southern blotting using as probe an internal oligomer corresponding to a segment of the c-ABL exon 2.
Tissue Distribution of Intact [S]ODNs . SCID mice were injected (1 mg/d for 12 consecutive days) with b2/a2 plus c-myc AS [S]ODNs. 24 h after the last injection, DNA obtained from 106 cells of various tissues was subjected to electrophoresis, and intracellular [S]ODNs were detected by specific hybridization with complementary oligoprobes as previously described (19) . For detection of intact [S] ODNs in BV173 cells infiltrating mouse tissues, leukemic SCID mice were injected (1 mg/d for 12 consecutive days) with bcr-abl, c-myc, or b2/a2 plus c-myc AS [S]ODNs. 24 h after the last injection, CD10+ BV173 were isolated by immunosorting from bone marrow and spleen cell suspensions. After DNA isolation, intracellular [S]ODNs were detected as described (19) .
Results
Effects of bcr-abl and/or c-myc AS [S]ODNs on BV173 Cells. In vitro, proliferation of Philadelphia I-positive BV173 cells that carry the bcr exon 2-abl exon 2 (b2/a2) junction was completely inhibited in the presence of b2/a2 or c-myc AS ODNs at a concentration of 10 N , g/ml each ( Fig . 1 A) , whereas, in combination, the [S]ODNs inhibited proliferation at a two-and fourfold lower final concentration, i.e ., concentrations at which the individual [S]ODNs were nearly or completely ineffective (Fig. 1 A) . S [S]ODNs were noninhibitory at any concentration tested . BV173 cell proliferation was equally inhibited by a 15-mer c-myc AS [S]ODN (5' AAC GTT GAG GGG CAT 3') . In contrast, a c-mycscrambled sequence (5' AAG CAT ACG GGG TGT 3') including the G tetrad reported to exert nonspecific antiproliferative effects on epithelial cells (23) (24) . The degraded, low-molecular weight DNA from apoptotic cells is generally extracted before and during the staining procedure; such cells, as well as the apoptotic bodies, stain with much lower intensity with the DNA fluorochromes, representing the "sub-G l " cell population on the DNA frequency histograms . The apoptotic mode of cell death was confirmed by observation of cell morphology after differential staining of DNA and protein (Fig . 1 D) . The changes characteristic of apoptosis, involving cell shrinkage, chromatin condensation, fragmentation of nuclei, hyperchromicity of chromatin, and shedding of apoptotic bodies, were observed in all cultures treated with b2/a2, c-myc, or a combination ofboth AS [S]ODNs . After 48 and especially after 72 h, there were numerous very late apoptotic cells in these cultures, containing very little or almost no stainable DNA (Fig. 1 D) . In all probability, these cells were represented on the DNA content frequency histograms by the distinct peaks near the origin of the DNA content coordinate, characteristic ofcells with minimal DNA content .
Effects of bcr-abl, c-myc, or bcr-abl plus c-myc AS [S]ODNs on Leukemia Progression in SCID Mice . We assessed the antileukemic effects ofbcr-abl and c-myc ODNs, alone and in combination, in immunodeficient SCID mice (males 8-10 wk old, 20-22 g) injected intravenously with 106 BV173 cells, a regimen that produces a disease process reminiscent of that in humans . 7 d later, mice were systemically injected for 12 consecutive days with 1 mg/d per mouse ofb2/a2 S plus c-myc S (6 d each, every other day), b2/a2 AS, c-myc AS, or b2/a2 plus c-myc AS (6 d each, every other day). Control mice were injected with diluent only. 4 wk after leukemia implantation, peripheral blood, spleen (SPL), and bone marrow (BMC) from one mouse per group were analyzed to assess the disease process. Immunofluorescence assay (sensitivity 10-Z) did not detect CD10+ leukemic cells, whereas colony assay (sensitivity 10-3) revealed several clonogenic leukemia cells in BMC suspensions of control and S [S]ODNs-treated mice, but none from cell suspensions of mice treated with AS [S]ODNs either individually or in combination (not shown) . RT-PCR amplification of bcrabl transcripts present in the total RNA isolated from BMC and SPL, followed by Southern blot hybridization, revealed a relatively strong signal from amplification products ofRNA isolated from control and S [S]ODN-treated mice, but only a weak signal in RNA derived from tissue of mice treated with individual ODNs, and a nearly undetectable signal in RNA from the mouse treated with both b2/a2 and c-myc AS [S]ODNs (not shown) . Equal amounts of [3-actin transcript were detected in RNA samples from each tissue.
8 wk after leukemia cell injection, the disease process was examined again in three mice (A, B, and C) from each group by immunofluorescence, colony assay, and RT-PCR using RNA ofvarious tissues . Immunofluorescence assay detected CD10+ cells in PBL (only one mouse was positive), SPL, and BMC of control and S [S]ODN-treated mice, but not in the corresponding tissues of the mice treated with AS ODNs (Table 1 ) . The more sensitive clonogenic assay revealed several leukemic colonies in PBL and abundant colonies in SPL and BMC of control and S [S]ODN-treated mice; in contrast, cell suspensions of c-myc or b2/a2 AStreated mice contained far fewer malignant colonogenic cells (Table 1) . Only one of the mice treated with both b2/a2 and c-myc AS ODNs contained detectable clonogenic leukemic cells. Scoring of superficial liver metastases was consistent with immunofluorescence and clonogenic assays (Table 2) . Numerous metastatic nodules were visible on the surface of livers from control and S-treated mice, several were visible on the liver of mice treated with single AS, and none were visible on the organs from mice treated with both AS [S]ODNs . RT-PCR amplification ofbcr-abl 1647 Skorski et al. (Fig. 2 A) . bcr-abl transcripts were also detected in all tissues except the brain ofmice treated with single AS [S]ODNs, but the signal was much weaker than that observed with control and S [S]ODN-treated mouse tissues . Even weaker signals were detected in the RNA isolated from all the organs except the brain of mice injected with b2/a2 plus c-myc AS [S]ODNs, suggesting that the leukemic cell load in mice treated with [S]ODNs in combination was reduced as compared with that ofmice treated with individual ODNs. The detection of equal amounts of (3-actin in each group of organs indicated the integrity and equal loading of the amplified products.
To confirm that the differences in the intensity of the bcr-abl bands corresponding to tissues of single versus combined AS [S]ODN-treated mice reflected the difference in amounts of bcr-abl transcript in the tissues, we performed Qt/RT-PCR using the same amount ofRNA isolated from (Table 3) . Analysis of leukemia progression in a separate set of experiments involving five mice per group confirmed the advantage of targeting cooperating versus individual oncogenes as a therapeutic strategy for tumor treatment (not shown) . Such differences among the groups of mice were reflected in their mortality rates ( Fig. 3 A) ; all nine control and nine S [S]ODN-treated mice died with diffuse leukemia, as confirmed by necropsy, 7-10 wk after intravenous injection of 106 BV173 leukemia cells (mean survival time 7.7 ± 0.8 and 8.3 ± 0.5 wk, respectively) . In contrast, the nine b2/a2 AS [S]ODN-and nine c-myc AS [S]ODNtreated mice died after 14-18 and 14-19 wk; of leukemia growth, respectively (mean survival time 14.7 ± 0.8 and 14.8 ± 0.9 wk, respectively ; P <0.001 compared with control or S-treated groups) . Nine mice treated with both AS [S]ODNs survived significantly longer (mean survival time 30.8 ± 10.9 wk; P <0.001 compared with mice treated with either AS ODNs).
In contrast, the combination ofb2/a2 and c-myc AS ODNs did not exert synergistic antitumor effect in SCID mice bearing Ph'-negative HL60 leukemic cells (Fig. 3 B) . All mean survival times were 7 .3 ± 0 .8, 11 .6 ± 0 .7, and 10 .4 ± 0.5 wk, respectively. Thus, the combination of bcr-abl (b2/a2) and c-myc AS ODNs exerted specific antitumor effects and was much more effective than individual AS ODNs in treating mice bearing Ph' leukemia . (Fig. 4 B) .
Discussion
The oncogene-targeted approach for the treatment of neoplastic disorders offers the possibility of selectively blocking the function of genes responsible for disease, as compared with the less selective antitumor effects of conventional chemotherapy and radiotherapy . Initial in vivo data in animal models suggest that targeting a single oncogene by AS [S] ODNs is associated with temporary suppression of tumor growth (19, (25) (26) (27) (28) . Because tumor formation is a multistep process involving altered function of several oncogenes, the success of oncogene-targeted therapy is likely to depend on the ability to target more than one gene critical for the maintenance of the tumor phenotype . In our studies involving multiple oncogenes targeting in CML cells, in addition to bcr-abl, we targeted c-myc because this gene appears to be necessary for the transforming ability of bcrabl (14-18), perhaps as one of the nuclear end points of BCR-ABL activity . Both bcr-abl and c-myc AS [S]ODNs can inhibit in vitro proliferation of Philadelphia' cells while sparing, at the doses used, that of erythromyeloid hematopoietic progenitor cells (20) (21) (22) 29) . In combination, these (19) might be insufficient to inhibit cell proliferation, wheras "partial" inhibition of two cooperating oncogenes might induce a more permanent block in the ability to proliferate . Our in vitro experiments using different concentrations of AS [S]ODNs separately and in combination do not exclude either possibility . In additional experiments, we found that the simultaneous down-regulation ofBCR-ABL and c-myb, but not BCR-ABL and DNA polymerase cx, exerted synergistic antitumor effects (data not shown) . This suggests that simultaneous inhibition of the expression of BCR/ABL and of other genes involved in proliferation of CML cells (i.e ., DNA polymerase a) does not necessarily exert synergistic antitumor effects, and raises the possibility that a functional relationship between BCR-ABL and other genes is required for these effects . The enhanced antileukemic effect observed with ODNs in combination was not associated with nonspecific toxicity on normal cells. Our previous studies showed that bcr-abl [S]ODNs used at doses similar to those used here were nontoxic to mice harboring leukemic cells (19) . In similar experiments, control mice injected with murine c-myc AS [S]ODNs revealed no major toxicity-associated morphological changes in the organs examined and no decrement in the proliferative capacity of BMC as indicated by clonogenic assays (not shown), suggesting that bcr-abl and c-myc AS [S]ODNs have favorable pharmacological properties in vivo. Systemic treatment with [S]ODNs was associated, however, with moderate hepatosplenomegaly, a not uncommon observation after injection of [S]ODNs (19, 28, 32) .
To exclude the possibility that the antileukemia effects were due to the nonspecific activity of [S]ODNs (33), several control experiments were performed . BV173 cells are not sensitive to b2/a2 or c-myc S [S]ODNs as well as to 6-bp mismatched AS [S]ODNs (19, 20) . Because the c-myc AS [S]ODN contains the G tetrad, a sequence shown to exert antiproliferative effects independent of an AS mechanism on cells growing in monolayer (23), we have used a c-mycscrambled [S]ODN preserving the G tetrad and found that it is nontoxic to BV173, HL60, and K562 cells (not shown) . The recent observation that closely spaced repeats of the consensus sequence GGC are critical for inhibition of BCR-ABL tyrosine kinase autophosphorylation (34), which is crucial for its transformation ability (35) , raises the possibility that AS [S]ODNs may act in an aptameric fashion . However, the [S]ODNs we had used do not contain closely spaced GGC sequences . Moreover, treatment of BV173 cells with b2/a2 AS [S]ODNs did not decrease the phosphorylation of p210 BCR-ABL and other proteins during the initial 48 h of incubation, and then the decrease in phosphorylation was proportional to the decrement in the p2 I OBCRIABL protein levels (not shown) . These two findings strongly argue against a primary aptameric mechanism as an explanation of the antileukemia effects seen with the (36) , but only the c-myc AS sequence was able to exert antitumor effect in SCID mice. Accordingly, it appears unlikely that this nonspecific mechanism of antitumor activity is an explanation for the AS effects we have observed in vivo. Moreover, b2/a2 AS [S]ODNs did not have antitumor effects against HL60 cells grown in SCID mice (19) , and the combination of b2/a2 plus c-myc AS ODNs did not exert synergistic antitumor effect against HL60 cells in SCID mice. Finally, to strengthen our data obtained with a CML cell line, experiments performed with CMLblast crisis primary cells growing in vitro and in vivo in SCID mice clearly demonstrate that the combination of bcr-abl and c-myc AS [S]ODNs had synergistic antileukemia effects (Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, G. Zon, R. V. Iozzo, and B . Calabretta, manuscript in preparation) .
The synergistic antileukemic effect exerted by targeting two cooperating oncogenes is similar to that observed for other types ofanticancer therapy such as combined chemotherapy or immunotherapy, in which different drugs are used to target tumor cells as they enter distinct cell cycle stages . The advantage ofantioncogene therapy rests in its selectivity for disease-inducing agents, and, in turn, its sparing of normal cells . Improvement in therapeutic potential by selection of optimal combinations of agents able to inhibit gene expression at different stages ofthe disease process (for example, proliferation and metastasis) or the combined use ofantioncogene and cytostatics agents (22) awaits more information on the functions and mechanism(s) of activation ofoncogenes in tumor cells .
